Intellipharmaceutics International Inc. (IPCI)

[Samsa]

absolutely, because every presentation they have made includes updates on that and they point out that the potential income for IPCI and partner is 600 million to 1 Billion depending on market saturation which is more than the 220 million to 440 million for Rexista. While they are at this moment concentrating on Rexista because of how near to filing it is. Pregabalin has the potential to be worth 3 times more. imagine the upfront payment if we are talking 25 to 50 million upfront with Rexista. Pregabalin could get 100 million upfront ! and if someone wants to get the jump start on the required trials now or early 2017 would be the time frame to ink the deal. unless like I said they want to do the trial themselves with money from Rexista. this could go either way but Pregabalin is bigger than Rexista and is ready for partnership.